Phio Pharmaceuticals Corp Stock Price, News & Analysis

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) has announced the rescheduling of its fireside chat with H.C. Wainwright, originally set for June 22, 2021. The new date is July 12, 2021, at 11 a.m. Eastern Time. Phio focuses on developing immuno-oncology therapeutics using its proprietary self-delivering RNAi (INTASYL™) platform, aimed at enhancing immune response against tumors. Investors can expect more details on the rescheduled event soon.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announces CEO Dr. Gerrit Dispersyn's participation in two key virtual events: the AGP Summer Healthcare Symposium on June 17, 2021 and a fireside chat hosted by H.C. Wainwright on June 22, 2021. These platforms will highlight the company's innovative self-delivering RNAi (INTASYL™) therapeutic platform, which aims to enhance immuno-oncology treatments. Interested parties can register for the fireside chat and access future webcasts via the company’s website.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced positive in vivo study results at the June 2021 ASCO Annual Meeting, showcasing its INTASYL™ RNAi therapy platform's efficacy in targeting BRD4 and PD-1 proteins. The dual-targeting approach led to complete tumor responses in 83% of tested mice, outperforming conventional treatments like JQ-1 and anti-PD-1 monoclonal antibodies. The study also indicated a superior safety profile for the INTASYL treatment. These findings emphasize INTASYL's potential in improving immuno-oncology therapies.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported financial results for Q1 2021, highlighting strong momentum in its pipeline. The company has significant data supporting its INTASYL compounds, showing potential to enhance CAR-T therapy efficacy. A clinical study for PH-762 in advanced melanoma is set to commence in Q4 2021, conducted at the Gustave Roussy Institute. Cash reserves reached $32.7 million, sufficient to fund operations into Q2 2023, despite a net loss of $3.4 million for the quarter. R&D expenses rose to $2.6 million, reflecting increased preclinical study costs.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising in vivo data on May 11, 2021, indicating that its compound PH-762 significantly boosts the antitumor efficacy of HER2-targeted CAR-T cells against solid tumors, particularly in a mouse model of ovarian cancer. The results show approximately 90% PD-1 silencing in HER2CART cells, enhancing their effectiveness without affecting cell viability. This breakthrough could improve T cell-based immunotherapies, addressing challenges faced by traditional CAR T-cell therapies in solid tumors.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced new data presentations at the upcoming 24th Annual Meeting of the ASGCT (May 11-14, 2021) and the ASCO Annual Meeting (June 4-8, 2021). At ASGCT, the poster titled "INTASYL PH-762 Self-Delivering RNAi Targeting PD-1 Enhances the Therapeutic Efficacy of HER2-Targeted CAR-T Cells" will be presented by Benjamin Cuiffo et al. Additionally, ASCO will feature a poster on INTASYL therapy targeting BRD4 and PD-1. Archived presentations will be available on the company's website.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) announced promising new in vivo data indicating that its INTASYL (mPH-762) therapy achieves significant tumor growth inhibition through intratumoral administration in both PD-1 responsive and refractory cancer models. This method shows potential for enhanced local immune checkpoint blockade without the systemic side effects of traditional therapies. The company plans to initiate a first-in-human clinical study for mPH-762 in advanced melanoma by Q4 2021, showcasing its commitment to advancing innovative cancer treatments.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) reported a net loss of $8.8 million for 2020, a slight improvement from $8.9 million in 2019. The company had cash of $14.2 million at year-end, up from $6.9 million in 2019, bolstered by $21.7 million raised in equity financing. Developmental progress includes new collaborations with AgonOx, Inc. and plans to initiate two clinical studies for PH-762 in 2021. R&D expenses rose to $4.4 million, while G&A expenses decreased to $4.4 million, reflecting reduced legal and hiring costs. Overall, the company maintains a solid financial outlook for the next two years.

Phio Pharmaceuticals Corp. announced new study data on its product candidate, PH-762, which targets PD-1 and shows promise in tumor control. This presentation will be part of the AACR Annual Meeting 2021, held virtually from April 10-15 and May 17-21. The poster titled "Intratumoral INTASYL™ self-delivering RNAi targeting PD-1" will explore the treatment's effects similar to systemic anti-PD-1 antibodies. Further details will be available on the Company’s website after the presentation.